Neos Therapeutics (NEOS) Rebounds 40% From Last Week’s Low: A Reversal Imminent?

There has been no news with regards to the commercial stage pharmaceutical firm Neos Therapeutics Inc (NASDAQ: NEOS) this week, but that didn’t stop the stock from emerging as a notable gainer.

The Neos stock had hit its week’s lowest point when it sank to $0.67 a share but has managed to recover from that point and has rallied by as high as 40%. Although there has been no news, it might be a good idea for investors to look into development from last month in order to get a better idea about Neos.

Related:  AzurRx BioPharma (AZRX) Takes a Severe Hit Amid Disappointing Data

Last month it was announced that the shareholders of Neos and those of the specialty pharmaceutical firm Aytu Biosciences was going to have a meeting on March 18, 2021, with regards to the prospective merger between the companies. It could be a major event and have a say on the proposed merger. Since the day is approaching, the Neos might have come into focus among investors.

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.